These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 32768596)

  • 21. Serum coding and non-coding RNAs as biomarkers of NAFLD and fibrosis severity.
    Di Mauro S; Scamporrino A; Petta S; Urbano F; Filippello A; Ragusa M; Di Martino MT; Scionti F; Grimaudo S; Pipitone RM; Privitera G; Di Pino A; Scicali R; Valenti L; Dongiovanni P; Fracanzani A; Rabuazzo AM; Craxì A; Purrello M; Purrello F; Piro S
    Liver Int; 2019 Sep; 39(9):1742-1754. PubMed ID: 31169972
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Visceral-to-Subcutaneous Abdominal Fat Ratio Is Associated with Nonalcoholic Fatty Liver Disease and Liver Fibrosis.
    Jung CH; Rhee EJ; Kwon H; Chang Y; Ryu S; Lee WY
    Endocrinol Metab (Seoul); 2020 Mar; 35(1):165-176. PubMed ID: 32207277
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Hyperhomocysteinemia--a predictor of inflammatory changes in the liver].
    Zviagintseva TD; Hlushchenko SV
    Lik Sprava; 2014 Nov; (11):154-5. PubMed ID: 25528857
    [TBL] [Abstract][Full Text] [Related]  

  • 24. High Prevalence of Nonalcoholic Fatty Liver Disease in Adolescents Undergoing Bariatric Surgery.
    Xanthakos SA; Jenkins TM; Kleiner DE; Boyce TW; Mourya R; Karns R; Brandt ML; Harmon CM; Helmrath MA; Michalsky MP; Courcoulas AP; Zeller MH; Inge TH;
    Gastroenterology; 2015 Sep; 149(3):623-34.e8. PubMed ID: 26026390
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Underappreciation of non-alcoholic fatty liver disease by primary care clinicians: limited awareness of surrogate markers of fibrosis.
    Patel PJ; Banh X; Horsfall LU; Hayward KL; Hossain F; Johnson T; Stuart KA; Brown NN; Saad N; Clouston A; Irvine KM; Russell AW; Valery PC; Williams S; Powell EE
    Intern Med J; 2018 Feb; 48(2):144-151. PubMed ID: 29083080
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Prevalence and Risk Factors of Nonalcoholic Fatty Liver Disease and Advanced Fibrosis in General Population: the French Nationwide NASH-CO Study.
    Nabi O; Lacombe K; Boursier J; Mathurin P; Zins M; Serfaty L
    Gastroenterology; 2020 Aug; 159(2):791-793.e2. PubMed ID: 32376412
    [No Abstract]   [Full Text] [Related]  

  • 27. The evaluation of hepatic fibrosis scores in children with nonalcoholic fatty liver disease.
    Mansoor S; Yerian L; Kohli R; Xanthakos S; Angulo P; Ling S; Lopez R; Christine CK; Feldstein AE; Alkhouri N
    Dig Dis Sci; 2015 May; 60(5):1440-7. PubMed ID: 25540086
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Clinical Presentation and Patient Evaluation in Nonalcoholic Fatty Liver Disease.
    Patel V; Sanyal AJ; Sterling R
    Clin Liver Dis; 2016 May; 20(2):277-92. PubMed ID: 27063269
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Enriched MACK-3 following CHAI and MACK-3 for the noninvasive diagnosis of nonalcoholic steatohepatitis.
    Polyzos SA; Kountouras J
    Ann Hepatol; 2020; 19(5):579-580. PubMed ID: 32702498
    [No Abstract]   [Full Text] [Related]  

  • 30. Development and Validation of Hepamet Fibrosis Scoring System-A Simple, Noninvasive Test to Identify Patients With Nonalcoholic Fatty Liver Disease With Advanced Fibrosis.
    Ampuero J; Pais R; Aller R; Gallego-Durán R; Crespo J; García-Monzón C; Boursier J; Vilar E; Petta S; Zheng MH; Escudero D; Calleja JL; Aspichueta P; Diago M; Rosales JM; Caballería J; Gómez-Camarero J; Lo Iacono O; Benlloch S; Albillos A; Turnes J; Banales JM; Ratziu V; Romero-Gómez M;
    Clin Gastroenterol Hepatol; 2020 Jan; 18(1):216-225.e5. PubMed ID: 31195161
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Serum metabolites detect the presence of advanced fibrosis in derivation and validation cohorts of patients with non-alcoholic fatty liver disease.
    Caussy C; Ajmera VH; Puri P; Hsu CL; Bassirian S; Mgdsyan M; Singh S; Faulkner C; Valasek MA; Rizo E; Richards L; Brenner DA; Sirlin CB; Sanyal AJ; Loomba R
    Gut; 2019 Oct; 68(10):1884-1892. PubMed ID: 30567742
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Non-invasive prediction of NAFLD severity: a comprehensive, independent validation of previously postulated serum microRNA biomarkers.
    López-Riera M; Conde I; Quintas G; Pedrola L; Zaragoza Á; Perez-Rojas J; Salcedo M; Benlloch S; Castell JV; Jover R
    Sci Rep; 2018 Jul; 8(1):10606. PubMed ID: 30006517
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Predictors of nonalcoholic steatohepatitis and significant fibrosis in non-obese nonalcoholic fatty liver disease.
    Kim D; Kim W; Joo SK; Kim JH; Harrison SA; Younossi ZM; Ahmed A
    Liver Int; 2019 Feb; 39(2):332-341. PubMed ID: 30298568
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Elevated Hemoglobin Level Is Associated With Advanced Fibrosis in Pediatric Nonalcoholic Fatty Liver Disease.
    Giorgio V; Mosca A; Alterio A; Alisi A; Grieco A; Nobili V; Miele L
    J Pediatr Gastroenterol Nutr; 2017 Aug; 65(2):150-155. PubMed ID: 28737569
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Predictors of advanced fibrosis in elderly patients with biopsy-confirmed nonalcoholic fatty liver disease: the GOASIA study.
    Pitisuttithum P; Chan WK; Piyachaturawat P; Imajo K; Nakajima A; Seki Y; Kasama K; Kakizaki S; Fan JG; Song MJ; Yoon SK; Dan YY; Lesmana L; Ho KY; Goh KL; Wong VWS; Treeprasertsuk S
    BMC Gastroenterol; 2020 Apr; 20(1):88. PubMed ID: 32252638
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Circulating periostin in patients with nonalcoholic fatty liver disease.
    Polyzos SA; Kountouras J; Anastasilakis AD; Papatheodorou A; Kokkoris P; Terpos E
    Endocrine; 2017 May; 56(2):438-441. PubMed ID: 27738886
    [No Abstract]   [Full Text] [Related]  

  • 37. The role of neutrophil to lymphocyte ratio for the assessment of liver fibrosis and cirrhosis: a systematic review.
    Peng Y; Li Y; He Y; Wei Q; Xie Q; Zhang L; Xia Y; Zhou X; Zhang L; Feng X; Chen K; Chen S; Chen W; Long Q; Chai J
    Expert Rev Gastroenterol Hepatol; 2018 May; 12(5):503-513. PubMed ID: 29629626
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A Comparison of Brunt's Criteria, the Non-Alcoholic Fatty Liver Disease Activity Score (NAS), and a Proposed NAS Scoring that Includes Fibrosis in Non-Alcoholic Fatty Liver Disease Staging.
    Santiago-Rolón A; Purcell D; Rosado K; Toro DH
    P R Health Sci J; 2015 Dec; 34(4):189-94. PubMed ID: 26602577
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Fibrosis-4 Index vs Nonalcoholic Fatty Liver Disease Fibrosis Score in Identifying Advanced Fibrosis in Subjects With Nonalcoholic Fatty Liver Disease: A Meta-Analysis.
    Castellana M; Donghia R; Guerra V; Procino F; Castellana F; Zupo R; Lampignano L; Sardone R; De Pergola G; Romanelli F; Trimboli P; Giannelli G
    Am J Gastroenterol; 2021 Sep; 116(9):1833-1841. PubMed ID: 34160377
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Hyperuricemia is not associated with severity of liver fibrosis in patients with nonalcoholic fatty liver disease: a systematic review and meta-analysis.
    Jaruvongvanich V; Ahuja W; Wijarnpreecha K; Ungprasert P
    Eur J Gastroenterol Hepatol; 2017 Jun; 29(6):694-697. PubMed ID: 28252464
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.